10-KPeriod: FY2014

BIOGEN INC. Annual Report, Year Ended Dec 31, 2014

Filed February 4, 2015For Securities:BIIB

Summary

Biogen Idec Inc.'s 2014 10-K filing highlights a significant year of growth, primarily driven by the strong performance of its Multiple Sclerosis (MS) franchise, particularly the newly launched TECFIDERA, which saw a 232.1% revenue increase. Total revenues grew by 40% year-over-year to $9.7 billion, with income from operations and net income also showing substantial increases of 57.9% and 57.6%, respectively. The company's strategic focus on neurological, autoimmune, and hematologic disorders is evident in its product portfolio and robust R&D investment, which increased by 31.1% to $1.89 billion. The company has also made significant strides in the hemophilia market with the launches of ALPROLIX and ELOCTATE, contributing $76 million and $58.4 million in revenue respectively in their launch year. These developments, coupled with strong performance in TYSABRI and AVONEX, position Biogen Idec for continued growth, though the company acknowledges intense competition and ongoing pricing pressures in the biopharmaceutical industry. The report also underscores the importance of its R&D pipeline, with investments in early and late-stage programs across key therapeutic areas, signaling a commitment to future innovation.

Financial Highlights

55 data points
Beta

Revenue

$9.70B

87.9% Gross Margin

Net Income

$2.93B

30.2% Net Margin

EPS (Diluted)

$12.37

Total Assets

$14.31B

Cash & Equivalents

$1.20B

Free Cash Flow

$2.65B

Financial Statements
Beta
Revenue$9.70B
Cost of Revenue$1.17B
Gross Profit$8.53B
SG&A Expenses$2.23B
Operating Expenses$5.75B
Operating Income$3.97B
Interest Expense$29.50M
Net Income$2.93B
EPS (Basic)$12.42
EPS (Diluted)$12.37
Shares Outstanding (Basic)236.40M
Shares Outstanding (Diluted)237.20M

Key Highlights

  • 1Total revenues increased by 40.0% to $9.7 billion in 2014, driven by strong product sales.
  • 2TECFIDERA revenue surged by 232.1% to $2.91 billion, showcasing its rapid market adoption.
  • 3Income from operations grew by 57.9% to $3.97 billion, and net income attributable to Biogen Idec Inc. rose by 57.6% to $2.93 billion.
  • 4Research and development expenses increased by 31.1% to $1.89 billion, reflecting a strong commitment to pipeline advancement.
  • 5Launched ALPROLIX and ELOCTATE for hemophilia A and B, generating $76.0 million and $58.4 million in revenue in their respective launch years.
  • 6Cash, cash equivalents, and marketable securities increased significantly by 79.4% to $3.32 billion, providing financial flexibility.

Frequently Asked Questions

The primary driver of Biogen Idec's significant revenue growth in 2014 was the exceptional performance of TECFIDERA, a treatment for Multiple Sclerosis (MS), which saw its revenue increase by 232.1% to $2.91 billion. Additionally, TYSABRI and AVONEX, other key MS treatments, continued to contribute substantially to overall revenue, along with the recent launches of hemophilia treatments ALPROLIX and ELOCTATE.

Biogen Idec is heavily investing in its future growth through robust research and development (R&D) initiatives. R&D expenses increased by 31.1% to $1.89 billion in 2014, focusing on early and late-stage programs in its core therapeutic areas of neurology, immunology, and hematology. Key pipeline areas include treatments for MS, Alzheimer's disease, and spinal muscular atrophy.

Biogen Idec faces several key risks, including substantial dependence on its principal products, intense competition from other biopharmaceutical companies and the potential impact of generic and biosimilar products. The company also notes risks related to pricing pressures, reimbursement policies from third-party payors, potential safety or efficacy issues with its products, and the challenges inherent in drug development and obtaining regulatory approvals.

The company ended 2014 with a strong financial position, reporting $3.32 billion in cash, cash equivalents, and marketable securities, a significant increase from the previous year. This liquidity, combined with operating cash flows, provides ample resources to fund ongoing operations, R&D, capital expenditures, and potential business development activities. The company also has a significant share repurchase program in place.